Skip to main content
SpringerLink
Log in

Pneumococcal 7-valent conjugate vaccine protects young children

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1
Fig 1.
Table 2

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Darkes MJM, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002: 4(9): 609–30

    PubMed  Google Scholar 

  2. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccine of healthy infants and young children. JAMA 2000; 283(11): 1460–8

    Article  PubMed  CAS  Google Scholar 

  3. Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Paediatr Health Care 2001; 15(4): 203–8

    CAS  Google Scholar 

  4. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Paediatr Infect Dis J 1999; 18(6): 543–51

    Article  CAS  Google Scholar 

  5. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR Morb Mortal Wkly Rep 2000 Oct 6; 49 (RR-9): 1–35

    Google Scholar 

  6. Hausdorf WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 2001; 357: 950–2

    Article  Google Scholar 

  7. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165 Suppl. 1: S49–52

    Article  PubMed  CAS  Google Scholar 

  8. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6): 403–9

    Article  PubMed  CAS  Google Scholar 

  9. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18(9): 757–63

    Article  PubMed  CAS  Google Scholar 

  10. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19(3): 187–95

    Article  PubMed  CAS  Google Scholar 

  11. Nurka A, Åhman H, Korkeila M, et al. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20(1): 25–33

    Article  Google Scholar 

  12. Choo S, Seymour L, Morris R, et al. Immunogenicity and reactogenicity of pneumococcal conjugate vaccine administered combined with Haemophilus influenzae type b conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 2000; 19(9): 854–62

    Article  PubMed  CAS  Google Scholar 

  13. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101 (4 Pt 1): 604–11

    Article  PubMed  CAS  Google Scholar 

  14. Barnett ED, Pelton SI, Cabral HJ, et al. Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children. Clin Infect Dis 1999; 29(1): 191–2

    Article  PubMed  CAS  Google Scholar 

  15. Srenson RU, Leiva LE, Giangrosso PA, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 1998; 17(8): 685–91

    Article  Google Scholar 

  16. O’Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease. Pediatrics 2000; 106(5): 965–72

    Article  PubMed  Google Scholar 

  17. Choo S, Zhang Q, Seymour L, et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000; 182(4): 1260–3

    Article  PubMed  CAS  Google Scholar 

  18. Black SB, Shinefield HR, Hansen J, et al. Postlicense evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20(12): 1105–7

    Article  PubMed  CAS  Google Scholar 

  19. Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171: 885–9

    Article  PubMed  CAS  Google Scholar 

  20. British National Formulary 44 [online]. Available from URL: http://www.bnf.org.uk [Accessed 2003 Mar 13]

  21. Prevnar, pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) [prescribing information]. Pearl River (NY): Lederle Laboratories, 2001

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pneumococcal 7-valent conjugate vaccine protects young children. Drugs Ther. Perspect 19, 1–4 (2003). https://doi.org/10.2165/00042310-200319070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319070-00001

Keywords

Search

Navigation